Orexigen Therapeutics, Inc. 4
4 · Orexigen Therapeutics, Inc. · Filed Jul 29, 2013
Insider Transaction Report
Form 4
Booth Mark D
Chief Commercial Officer
Transactions
- Exercise/Conversion
Common Stock
2013-07-26$1.66/sh+64,767$107,513→ 64,767 total - Sale
Common Stock
2013-07-26$7.50/sh−20,000$150,000→ 29,045 total - Exercise/Conversion
Stock Option (right to buy)
2013-07-26−64,767→ 613,924 totalExercise: $1.66Exp: 2021-07-24→ Common Stock (64,767 underlying) - Sale
Common Stock
2013-07-26$7.75/sh−29,045$225,099→ 0 total - Sale
Common Stock
2013-07-26$7.25/sh−15,722$113,985→ 49,045 total
Footnotes (4)
- [F1]The exercise reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 23, 2013.
- [F2]The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 23, 2013.
- [F3]1/48th of the total number of shares of stock subject to the option (rounded down to the next whole number of shares) shall vest on the same day of each one-month period of the reporting person's service as an employee, director or consultant following July 25, 2011, so that all of the shares of the stock subject to the option shall be vested on July 25, 2015, subject to the reporting person's continued service relationship (whether as an employee, director or consultant) with the Company or any parent or subsidiary on each such date.
- [F4]Not applicable.